MIR5194: A Potential Drug Target and Biomarker (G100847051)

Target Name: MIR5194

NCBI ID: G100847051

MIR5194

Other Name(s): microRNA 5194 | hsa-miR-5194 | mir-5194 | hsa-mir-5194 | MicroRNA 5194

MIR5194: A Potential Drug Target and Biomarker

Molecular characterization of MIR5194, a gene encoding a protein known as melanoma invasion-associated gene (MIA), has revealed its potential as a drug target and biomarker in the fight against melanoma, one of the most aggressive forms of skin cancer. MIA is a transmembrane protein that plays a crucial role in the invasive and metastatic processes of melanoma. Its expression has been identified as a predictor of cancer-related outcomes in various types of cancer, including melanoma. Therefore, targeting MIA with drugs has the potential to significantly improve treatment outcomes for this aggressive form of skin cancer.

MIA is a 21-kDa protein that is expressed in various tissues, including skin, hair, and nails. It is involved in cell signaling processes, including cell adhesion, migration, and invasion. MIA has been implicated in the development and progression of various types of cancer due to its involvement in cell signaling pathways. For example, MIA has been shown to be involved in the regulation of cell growth, apoptosis, and angiogenesis.

In melanoma, MIA is overexpressed in many tissues, including the skin, and has been associated with the development and progression of melanoma tumors. MIA has also been shown to promote the growth and survival of melanoma cells in cell culture and animal models.

Targeting MIA with drugs has the potential to inhibit its functions and reduce the growth and survival of melanoma cells. This could lead to a reduction in the severity and progression of melanoma tumors. Therefore, the study of MIA as a potential drug target and biomarker is of great interest.

Drugs that target MIA have the potential to be developed into new treatments for melanoma. For example, inhibitors of MIA have been shown to be effective in preclinical models of melanoma treatment. These inhibitors have been shown to reduce the growth and survival of melanoma cells, leading to a reduction in the severity and progression of melanoma tumors.

In addition to its potential as a drug target, MIA has also been identified as a potential biomarker for melanoma. Its overexpression has been shown to be associated with the development and progression of melanoma in various types of cancer. Therefore, measuring the expression of MIA has the potential to be used as a biomarker for melanoma, allowing for the early detection and treatment of this aggressive form of skin cancer.

In conclusion, MIR5194 is a potential drug target and biomarker for melanoma. Its involvement in cell signaling pathways and its overexpression in melanoma cells make it an attractive target for drug development. Further research is needed to fully understand the functions of MIR5194 in melanoma and its potential as a drug and biomarker.

Protein Name: MicroRNA 5194

The "MIR5194 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about MIR5194 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets